Core Insights - Cosmos Health Inc. has purchased $600,000 worth of Bitcoin, increasing its total investment in digital assets to $3.1 million, which includes holdings in Bitcoin and Ethereum [1][2] Group 1: Digital Asset Strategy - The CEO of Cosmos Health, Greg Siokas, emphasized that the company views select digital assets as an attractive asset class with significant upside potential [2] - The company's strategy involves a disciplined treasury approach aimed at enhancing balance sheet diversification while maintaining financial flexibility [2][3] - The digital assets are intended to provide additional financial flexibility and may be monetized to address the current discount to book value and support shareholder value initiatives [3] Group 2: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [3] - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands and manufactures products under European Good Manufacturing Practices (GMP) [3] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals and has established R&D partnerships targeting major health disorders, enhanced by AI drug repurposing technologies [3]

Core Viewpoint - Cosmos Health Inc. has entered into a Letter of Intent to acquire a pharmacy distribution network in Greece, aiming to enhance its commercial reach and operational efficiencies [1][3][4]. Group 1: Acquisition Details - The acquisition involves a pharmacy distribution network that generates approximately €10 million (around $11.5 million) in annual gross revenue [2]. - The Letter of Intent is valid for ninety days from March 6, 2026 [1]. Group 2: Strategic Implications - The acquisition is expected to strengthen CosmoFarm's distribution footprint and improve operating efficiencies through integration with its automated logistics platform [3]. - This transaction is part of Cosmos Health's broader strategy to achieve a revenue target of $155.8 million for 2027, combining organic growth and acquisitions [4]. Group 3: Leadership Perspective - CEO Greg Siok emphasized that the acquisition aligns with the company's strategy to enhance its pharmaceutical distribution platform and support revenue growth and profitability [5].

Core Insights - Cosmos Health Inc. is evaluating strategic monetization options for its real estate portfolio to unlock shareholder value, highlighting the intrinsic value of its assets [1][14] Real Estate Valuation - The combined fair market value of the Company's Cana Laboratories manufacturing facility and CosmoFarm logistics center is estimated at approximately $15 million, excluding machinery and equipment [2] - The estimated value is supported by favorable macro conditions in the Greek property market, with residential property prices surpassing their 2008 pre-financial crisis peak [3] - The fair market value of the Company's real estate assets exceeds its current market capitalization of approximately $13.5 million as of February 17, 2026 [4] Property Details - Cana Laboratories is located in Neo Iraklio, Athens, comprising approximately 54,000 square feet of land and 35,700 square feet of constructed area, with potential for additional buildable capacity [7] - The property is strategically located with access to major highways and proximity to Athens International Airport and commercial centers [8] - CosmoFarm Logistics Center in Peristeri, Athens, consists of approximately 29,100 square feet and operates as a pharmaceutical wholesale and distribution hub [11] Strategic Options - The Company's market capitalization reflects a significant discount to its reported book value of $23.1 million as of Q3 2025, indicating substantial capital relative to its public equity value [12] - Potential monetization strategies include outright sale, joint ventures, sale-leaseback transactions, or other arrangements, with proceeds potentially used for debt reduction or reinvestment [13] - The CEO emphasized the disconnect between the current valuation and the intrinsic value of the assets, indicating a focus on evaluating monetization opportunities carefully [14]

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group established in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [5]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, through subsidiaries in Greece and the UK [5]. Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, thereby supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK and strengthens the company's market positioning across various retail platforms [5]. - This expansion is expected to increase brand reach and support the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Insights - Cosmos Health Inc. is expanding its retail presence in the UK by making its antimicrobial skin cleanser, C-Scrub, available through Superdrug, the second-largest beauty and health retailer in the UK [1][4]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [5]. - The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including C-Scrub, and operates under European Good Manufacturing Practices (GMP) [5]. - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders [5]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [4]. - The product's availability in Superdrug's extensive retail and pharmacy network enhances Cosmos Health's market positioning in the UK [4]. Group 3: Strategic Importance - The entry into Superdrug reinforces the retail momentum for C-Scrub in the UK, significantly strengthening the company's market positioning across various retail platforms [5]. - This expansion increases brand reach and supports the long-term development of Cosmos Health's broader product portfolio in the region [5].

Core Viewpoint - Cosmos Health Inc. has significantly expanded its retail presence in the UK by launching its antimicrobial skin cleanser, C-Scrub, through Tesco, the largest retailer in the UK, enhancing the product's visibility and market credibility [1][3][6]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [7]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary, Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [7]. - Cosmos Health has established R&D partnerships targeting major health disorders and focuses on the development of novel patented nutraceuticals and innovative OTC products [7][8]. Group 2: Product and Market Expansion - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [5]. - The entry of C-Scrub into Tesco represents a pivotal moment for Cosmos Health, significantly enhancing its retail presence and credibility in the market [6]. - The company anticipates continued momentum for C-Scrub in the UK as it strengthens retail partnerships and expands its distribution footprint [5][6]. Group 3: Retail Partnership - Tesco, as the UK's largest retailer, holds nearly 30% market share and generates over $80 billion in annual revenue, serving millions of customers weekly [2]. - The partnership with Tesco is expected to provide a robust platform for the potential rollout of additional products from Cosmos Health's portfolio in the future [6].

Core Insights - Cosmos Health Inc. participated in the World Health Expo Dubai 2026, one of the largest healthcare exhibitions globally, held from February 9-12, 2026 [1][3] - The event attracted over 235,000 visitors and 4,300 exhibitors from more than 180 countries, facilitating collaboration among healthcare leaders and innovators [3] Company Highlights - Cosmos Health showcased its proprietary nutraceutical and wellness brands, particularly the Sky Premium Life® line, which is gaining traction through expanded distribution and new product introductions [4][6] - The company also highlighted other brands such as C-Scrub®, an antiseptic wash, and Mediterranation®, a luxury nutritional supplement line featuring organic herbs from the Mediterranean [5][6] - The participation at the Expo allowed Cosmos Health to raise awareness of its manufacturing capabilities and engage with potential partners and distributors [6] Strategic Goals - CEO Greg Siok emphasized the company's commitment to expanding its global footprint and strengthening strategic relationships during the Expo [7] - The company is focused on disciplined growth, brand development, and long-term value creation, with ongoing discussions for potential agreements in regions including Japan, China, and Latin America [7] Company Overview - Cosmos Health Inc., incorporated in 2009, is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands [8] - The company operates under European Good Manufacturing Practices and is involved in manufacturing pharmaceuticals, food supplements, and medical devices within the EU [8] - Cosmos Health is expanding its distribution across Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [8]

Core Viewpoint - Cosmos Health Inc. is expanding its digital assets program by purchasing $500,000 of Bitcoin, indicating a disciplined and flexible approach to capital deployment [1][5]. Digital Assets Program - The digital assets program has primarily focused on Ethereum, but the addition of Bitcoin marks a strategic evolution to broaden exposure to established digital assets [2]. - The company is also considering the inclusion of additional cryptocurrencies based on market conditions and alignment with its financial strategy, enhancing flexibility and diversification [3]. Investment Details - To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, which includes its Ethereum holdings and the recent Bitcoin investment [4]. - The Bitcoin investment was executed at an average price below $70,000 per Bitcoin, reflecting the company's strategy to deploy capital during market sell-offs [5]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6]. - The company manufactures and distributes a wide range of healthcare products and has established R&D partnerships targeting major health disorders, enhanced by AI technologies [6]. - Cosmos Health is expanding its operations globally, with distribution centers in Europe, Asia, and North America [6].

Core Viewpoint - Cosmos Health Inc. continues to experience operational growth and infrastructure expansion through its subsidiary Cosmofarm, particularly in the pharmaceutical distribution sector in Greece [1]. Group 1: Customer Growth and Financial Performance - In 2025, Cosmofarm added nearly 100 new pharmacy customers, resulting in a 20% increase in its active customer base [2]. - Annual revenue per customer increased by approximately 12%, while profitability per customer improved by around 14%, attributed to enhanced route density and optimized order execution [2]. - Management anticipates that customer growth will continue at similar or higher rates in 2026 based on current onboarding activity and demand trends [2]. Group 2: Infrastructure and Automation Investments - Cosmofarm introduced three new delivery routes in the Attica region to enhance service quality and last-mile delivery performance [3]. - The company has made multi-million dollar investments in automation and logistics infrastructure, including advanced robotic systems for procurement and order fulfillment [4]. - A capital investment program of approximately $1 million is currently underway to expand robotic capacity and throughput [4]. Group 3: Revenue Potential and Operational Efficiency - The expanded ROWA and A-frame robotic picking line is expected to materially increase processing capacity and support an incremental annual revenue potential of approximately $40 million [7]. - The company is upgrading its 29,000-square-foot property in Athens to modernize office space and enhance distribution capabilities [8]. - CEO Greg Siokas emphasized that ongoing investments in automation will significantly expand capacity and support sustainable growth and long-term value creation for Cosmos Health [10].

Core Viewpoint - Cosmos Health Inc. has entered into a manufacturing and supply agreement with Libytec Pharmaceutical S.A. for the production of the pharmaceutical product PathMuscle, enhancing its operational capabilities and revenue visibility in the European market [1][6][7]. Group 1: Agreement Details - The agreement entails Cosmos Health being responsible for the complete manufacturing process of PathMuscle, including formulation, production, quality control, and product release, adhering to regulatory requirements [2]. - The product PathMuscle is a fixed-dose combination of thiocolchicoside and paracetamol, aimed at treating musculoskeletal conditions by providing muscle relaxation and pain relief [3]. - PathMuscle is available in multiple oral presentations, including film-coated tablets and soluble tablets, and is indicated for the treatment of painful muscle spasms associated with acute musculoskeletal disorders [4]. Group 2: Production Volumes - The agreement specifies minimum committed production volumes of 591,500 units, with cumulative production volumes over five years expected to exceed 1.2 million units, depending on market demand [5]. Group 3: Strategic Implications - This agreement reflects Cosmos Health's vertically integrated manufacturing capabilities and is anticipated to improve capacity utilization and enhance revenue visibility across its operations [6]. - The CEO of Cosmos Health emphasized that this collaboration supports the company's strategic focus on expanding pharmaceutical manufacturing through long-term partnerships, showcasing its operational strength and regulatory expertise [7]. Group 4: Company Overview - Cosmos Health Inc. is a diversified global healthcare group, incorporated in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands, and operates under European Good Manufacturing Practices [8]. - The company is involved in manufacturing pharmaceuticals, food supplements, and medical devices, and has established R&D partnerships targeting major health disorders, while also expanding its distribution network across Europe, Asia, and North America [8].